|Videos|June 2, 2017

How Can Behavioral Change Interventions Improve Antibiotic Prescribing?

Conan MacDougall, PharmD, discusses how behavioral change interventions can positively impact the antibiotic prescribing environment.

Conan MacDougall, PharmD, professor of clinical pharmacy, University of California, San Francisco, discusses how behavioral change interventions can positively impact the antibiotic prescribing environment.

Interview Transcript (slightly modified for readability)

“When you’re thinking about the effects of behavioral change, it’s important to think about both the effectiveness of different strategies and their efficiency. So, strategies like audited feedback that are typically used in antimicrobial stewardship are very effective, but they’re not necessarily efficient; they require a lot of manpower, a lot of time.

Other strategies that involve changing the antibiotic prescribing environment, what we might call ‘behavioral nudges,’ might be less effective on a per interaction basis, but can be scaled quickly using technology, so these might be things like changing antibiotic order entry set, or providing feedback to providers on how their antibiotic prescribing is similar to or different than other prescribers and how it meets institutional goals.”


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.